Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 19 December 2025 are set out below…
Justice Burley of the Federal Court has delivered judgment in proceedings between CPC Patent Technologies Pty Ltd (CPC) and Apple Pty Limited and Apple Inc (collectively, Apple), concerning alleged patent infringement by Apple’s biometric security…
Full Court Resurrects Computer-Implemented Inventions from the Patent Graveyard. In a significant development in the long-running Aristocrat patent saga, the Full Court of the Federal Court has allowed Aristocrat Technologies Australia…
Swiss-style (or Swiss-type) patent claims have been routinely sought and granted in New Zealand for many years. However, the New Zealand courts are yet to determine the question of what conduct will infringe such a claim.
Sally Paterson and Paul Johns discuss and compare various intellectual property laws in New Zealand that provide protection for three-dimensional designs and shapes.
On 5 December 2025, Justice Burley of the Federal Court of Australia granted Janssen a preliminary injunction to restrain Juno Pharmaceuticals from launching generic versions of paliperidone palmitate long acting injectables (LAIs)…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 12 December 2025 are set out below…
Pearce IP’s CEO, Naomi Pearce, speaks with our Heads of Litigation for Australia and New Zealand about the practice of “skinny labelling” of generic drugs. They discuss whether a “skinny label” approach will assist in avoiding patent infringement of method of treatment or Swiss-style claims in Australia and New Zealand respectively.
Pearce IP and Leaders Recognised in Chambers Asia-Pacific 2026 Rankings for Third Consecutive Year
This article is the second in a series that explores the history of Swiss-style (Swiss-type) claims in New Zealand, the relevant law and policy considerations, and the likely judicial approach to the question of infringement.
High Court Draws Clear Line Between Trade Mark Infringement and Misleading & Deceptive Conduct in Bed Bath N’ Table Case
Swiss-style patent claims (often referred to as Swiss-type claims in New Zealand) have been routinely sought and granted in New Zealand for many years. However, the New Zealand courts are yet to determine the question of what conduct will infringe such a claim. This article is the first in a series of three that will explore the history of Swiss-style claims in New Zealand, the relevant law and policy considerations, and the likely judicial approach to the question of infringement.
The End of an Era for Pharma PTEs in AU: Full Court Excludes Formulation Patent Term Extensions in Aripiprazole (ABILIFY) Appeal
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 5 December 2025 are set out below…
This morning the Full Court published its decision in Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd [2025] FCAFC 161 confirming that pharmaceutical formulation patents are no longer eligible for a patent term extension in Australia.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 28 November 2025 are set out below…
Founder and CEO of Pearce IP, Naomi Pearce, has been recognised as the 2026 Client Choice Award winner for Intellectual Property – Patents (Australia) by Lexology. Established in 2005, the Client Choice Awards celebrate those law firms and partners around the world who stand apart for the excellence of their client care and quality of service.
The Australian Federal Court addressed when a successful applicant in patent infringement proceedings must make an election between damages and an account of profits. The answer is: promptly, once they are in a sufficiently informed position to make a meaningful decision.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 21 November 2025 are set out below…
Two years ago, Pearce IP made the decision to put its employee’s first by introducing a raft of reproductive leave options for all permanent employees. With a workforce that’s 88% female and witnessing the impact of…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 14 November 2025 are set out below…
Pearce IP’s CEO & Founder Naomi Pearce recognised in IAM Global Leaders 2026 which showcases patent leaders in IAM Patent 1000 gold tier who merit special attention.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 7 November 2025 are set out below…
In a lengthy judgment, Justice Nicholas of the Federal Court of Australia has dismissed Sanofi’s appeal to overturn the decision of the Delegate of the Commissioner of Patents dismissing Sanofi’s opposition to the grant of five Amgen patent applications…
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
